We propose a general chemotactic model describing a system of interacting elements. Each element in this model exhibits internal dynamics, and there exists a nonlinear coupling between elements that depends on their internal states. From this model, we derive a simpler model describing the phases and positions of the chemotactic elements by means of center-manifold and phase-reduction methods. We find that, despite its simplicity, the model obtained through this reduction exhibits a rich variety of patterns.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1103/PhysRevLett.99.134103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Decreased serum PF4 levels correlate with cognitive decline and CSF biomarkers in Alzheimer's disease in a Chinese cohort.
Exp Gerontol
January 2025
Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing 400042, China.
Background: Platelet factor 4 (PF4), a chemotactic factor secreted from the α-granules of platelets, has recently been proved to mitigate neuroinflammation and improve aging-related cognition decline, which may be involved in Alzheimer's disease (AD).
Objective: This study aims to investigate the alterations of serum PF4 levels in AD, the correlation between serum PF4 and β-amyloid (Aβ) and tau levels in cerebrospinal fluid (CSF), and the potential diagnostic utility of PF4 in AD.
Methods: A cross-sectional study was conducted involving 38 amyloid-positive AD patients and 50 cognitively normal controls.
Nanodevice-Mediated Immune Cell Recruitment: Targeting Senescent Cells via MMP-3-Responsive CXCL12-Coated Nanoparticles.
ACS Appl Mater Interfaces
January 2025
Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM) Universitat Politècnica de València, Universitat de València, Camino de Vera, s/n., 46022 Valencia, Spain.
Senescent cells are involved in age-related disorders in different organs and are therapeutic targets for fibrotic and chronic pathologies. Immune-modulating agents, able to enhance senescent cell detection and elimination by endogenous immune cells, have emerged as pharmacological strategies. We report herein a nanoparticle for immune cell-mediated senolytic therapy designed to recruit immune cells in response to specific enzymatic matrix metalloproteinase-3 (MMP-3) activity in the senescence-associated secretory phenotype.
View Article and Find Full Text PDFCorrelation between preoperative aqueous cytokine levels and mid-term corneal endothelial cell loss following penetrating keratoplasty.
Eye (Lond)
January 2025
Department of Ophthalmology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan.
Objective: To investigate the association between preoperative aqueous humour (AqH) cytokines and mid-term endothelial cell density (ECD) following penetrating keratoplasty (PKP).
Methods: This study analysed a total of 87 eyes of which 54 underwent PKP and 33 eyes underwent cataract surgery. AqH samples were collected at the beginning of surgery.
SOX11 silence inhibits atherosclerosis progression in ApoE-deficient mice by alleviating endothelial dysfunction.
Exp Cell Res
January 2025
Department of Internal Medicine, Hebei Medical University, Shijiazhuang, 050017, Hebei, China; Department of Cardiology, Hebei General Hospital, Shijiazhuang, 050051, Hebei, China. Electronic address:
SRY-Box Transcription Factor-11 (SOX11) is a transcriptional regulatory factor that plays a crucial role in inflammatory responses. However, its involvement in atherosclerosis (AS), a cardiovascular disease driven by endothelial cell inflammation, remains unknown. This study aims to elucidate the role of SOX11 in AS.
View Article and Find Full Text PDFImmunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3.
Biomedicines
December 2024
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Targeted therapies (e.g., ibrutinib) have markedly improved chronic lymphocytic leukemia (CLL) management; however, ~20% of patients experience disease relapse, suggesting the inadequate depth and durability of these front-line strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!